Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer

B Burford; A Gentry-Maharaj; R Graham; D Allen; J W Pedersen; A S Nudelman; Klas Ola Blixt; E O Fourkala; D Bueti; A Dawnay; J Ford; R Desai; L David; P Trinder; B Acres; T Schwientek; A Gammerman; C A Reis; Lara Patricia Marcos da Silva; H Osório; R Hallett; H H Wandall; U Mandel; M A Hollingsworth; I Jacobs; I Fentiman; H Clausen; J Taylor-Papadimitriou; U Menon; J M Burchell

doi:10.1038/bjc.2013.214

Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer

B Burford, A Gentry-Maharaj, R Graham, D Allen, J W Pedersen, A S Nudelman, Klas Ola Blixt, E O Fourkala, D Bueti, A Dawnay, J Ford, R Desai, L David, P Trinder, B Acres, T Schwientek, A Gammerman, C A Reis, Lara Patricia Marcos da Silva, H OsórioR Hallett, H H Wandall, U Mandel, M A Hollingsworth, I Jacobs, I Fentiman, H Clausen, J Taylor-Papadimitriou, U Menon, J M Burchell

43 Citations (Scopus)

Abstract

Background:Autoantibodies have been detected in sera before diagnosis of cancer leading to interest in their potential as screening/early detection biomarkers. As we have found autoantibodies to MUC1 glycopeptides to be elevated in early-stage breast cancer patients, in this study we analysed these autoantibodies in large population cohorts of sera taken before cancer diagnosis.Methods:Serum samples from women who subsequently developed breast cancer, and aged-matched controls, were identified from UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and Guernsey serum banks to formed discovery and validation sets. These were screened on a microarray platform of 60mer MUC1 glycopeptides and recombinant MUC1 containing 16 tandem repeats. Additional case-control sets comprised of women who subsequently developed ovarian, pancreatic and lung cancer were also screened on the arrays.Results:In the discovery (273 cases, 273 controls) and the two validation sets (UKCTOCS 426 cases, 426 controls; Guernsey 303 cases and 606 controls), no differences were found in autoantibody reactivity to MUC1 tandem repeat peptide or glycoforms between cases and controls. Furthermore, no differences were observed between ovarian, pancreatic and lung cancer cases and controls.Conclusion:This robust, validated study shows autoantibodies to MUC1 peptide or glycopeptides cannot be used for breast, ovarian, lung or pancreatic cancer screening. This has significant implications for research on the use of MUC1 in cancer detection.

Original language	English
Journal	B J C
Volume	108
Issue number	10
Pages (from-to)	2045-55
Number of pages	11
ISSN	0007-0920
DOIs	https://doi.org/10.1038/bjc.2013.214
Publication status	Published - 28 May 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2013.214

Cite this

Burford, B., Gentry-Maharaj, A., Graham, R., Allen, D., Pedersen, J. W., Nudelman, A. S., Blixt, K. O., Fourkala, E. O., Bueti, D., Dawnay, A., Ford, J., Desai, R., David, L., Trinder, P., Acres, B., Schwientek, T., Gammerman, A., Reis, C. A., da Silva, L. P. M., ... Burchell, J. M. (2013). Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. B J C, 108(10), 2045-55. https://doi.org/10.1038/bjc.2013.214

Burford, B, Gentry-Maharaj, A, Graham, R, Allen, D, Pedersen, JW, Nudelman, AS, Blixt, KO, Fourkala, EO, Bueti, D, Dawnay, A, Ford, J, Desai, R, David, L, Trinder, P, Acres, B, Schwientek, T, Gammerman, A, Reis, CA, da Silva, LPM, Osório, H, Hallett, R, Wandall, HH , Mandel, U, Hollingsworth, MA, Jacobs, I, Fentiman, I, Clausen, H, Taylor-Papadimitriou, J, Menon, U & Burchell, JM 2013, 'Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer', B J C, vol. 108, no. 10, pp. 2045-55. https://doi.org/10.1038/bjc.2013.214

@article{f953015c6aa942d981f689e088cb876b,

title = "Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer",

abstract = "Background:Autoantibodies have been detected in sera before diagnosis of cancer leading to interest in their potential as screening/early detection biomarkers. As we have found autoantibodies to MUC1 glycopeptides to be elevated in early-stage breast cancer patients, in this study we analysed these autoantibodies in large population cohorts of sera taken before cancer diagnosis.Methods:Serum samples from women who subsequently developed breast cancer, and aged-matched controls, were identified from UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and Guernsey serum banks to formed discovery and validation sets. These were screened on a microarray platform of 60mer MUC1 glycopeptides and recombinant MUC1 containing 16 tandem repeats. Additional case-control sets comprised of women who subsequently developed ovarian, pancreatic and lung cancer were also screened on the arrays.Results:In the discovery (273 cases, 273 controls) and the two validation sets (UKCTOCS 426 cases, 426 controls; Guernsey 303 cases and 606 controls), no differences were found in autoantibody reactivity to MUC1 tandem repeat peptide or glycoforms between cases and controls. Furthermore, no differences were observed between ovarian, pancreatic and lung cancer cases and controls.Conclusion:This robust, validated study shows autoantibodies to MUC1 peptide or glycopeptides cannot be used for breast, ovarian, lung or pancreatic cancer screening. This has significant implications for research on the use of MUC1 in cancer detection.",

author = "B Burford and A Gentry-Maharaj and R Graham and D Allen and Pedersen, {J W} and Nudelman, {A S} and Blixt, {Klas Ola} and Fourkala, {E O} and D Bueti and A Dawnay and J Ford and R Desai and L David and P Trinder and B Acres and T Schwientek and A Gammerman and Reis, {C A} and {da Silva}, {Lara Patricia Marcos} and H Os{\'o}rio and R Hallett and Wandall, {H H} and U Mandel and Hollingsworth, {M A} and I Jacobs and I Fentiman and H Clausen and J Taylor-Papadimitriou and U Menon and Burchell, {J M}",

year = "2013",

month = may,

day = "28",

doi = "10.1038/bjc.2013.214",

language = "English",

volume = "108",

pages = "2045--55",

journal = "B J C",

issn = "0007-0920",

publisher = "nature publishing group",

number = "10",

}

TY - JOUR

T1 - Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer

AU - Burford, B

AU - Gentry-Maharaj, A

AU - Graham, R

AU - Allen, D

AU - Pedersen, J W

AU - Nudelman, A S

AU - Blixt, Klas Ola

AU - Fourkala, E O

AU - Bueti, D

AU - Dawnay, A

AU - Ford, J

AU - Desai, R

AU - David, L

AU - Trinder, P

AU - Acres, B

AU - Schwientek, T

AU - Gammerman, A

AU - Reis, C A

AU - da Silva, Lara Patricia Marcos

AU - Osório, H

AU - Hallett, R

AU - Wandall, H H

AU - Mandel, U

AU - Hollingsworth, M A

AU - Jacobs, I

AU - Fentiman, I

AU - Clausen, H

AU - Taylor-Papadimitriou, J

AU - Menon, U

AU - Burchell, J M

PY - 2013/5/28

Y1 - 2013/5/28

N2 - Background:Autoantibodies have been detected in sera before diagnosis of cancer leading to interest in their potential as screening/early detection biomarkers. As we have found autoantibodies to MUC1 glycopeptides to be elevated in early-stage breast cancer patients, in this study we analysed these autoantibodies in large population cohorts of sera taken before cancer diagnosis.Methods:Serum samples from women who subsequently developed breast cancer, and aged-matched controls, were identified from UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and Guernsey serum banks to formed discovery and validation sets. These were screened on a microarray platform of 60mer MUC1 glycopeptides and recombinant MUC1 containing 16 tandem repeats. Additional case-control sets comprised of women who subsequently developed ovarian, pancreatic and lung cancer were also screened on the arrays.Results:In the discovery (273 cases, 273 controls) and the two validation sets (UKCTOCS 426 cases, 426 controls; Guernsey 303 cases and 606 controls), no differences were found in autoantibody reactivity to MUC1 tandem repeat peptide or glycoforms between cases and controls. Furthermore, no differences were observed between ovarian, pancreatic and lung cancer cases and controls.Conclusion:This robust, validated study shows autoantibodies to MUC1 peptide or glycopeptides cannot be used for breast, ovarian, lung or pancreatic cancer screening. This has significant implications for research on the use of MUC1 in cancer detection.

AB - Background:Autoantibodies have been detected in sera before diagnosis of cancer leading to interest in their potential as screening/early detection biomarkers. As we have found autoantibodies to MUC1 glycopeptides to be elevated in early-stage breast cancer patients, in this study we analysed these autoantibodies in large population cohorts of sera taken before cancer diagnosis.Methods:Serum samples from women who subsequently developed breast cancer, and aged-matched controls, were identified from UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and Guernsey serum banks to formed discovery and validation sets. These were screened on a microarray platform of 60mer MUC1 glycopeptides and recombinant MUC1 containing 16 tandem repeats. Additional case-control sets comprised of women who subsequently developed ovarian, pancreatic and lung cancer were also screened on the arrays.Results:In the discovery (273 cases, 273 controls) and the two validation sets (UKCTOCS 426 cases, 426 controls; Guernsey 303 cases and 606 controls), no differences were found in autoantibody reactivity to MUC1 tandem repeat peptide or glycoforms between cases and controls. Furthermore, no differences were observed between ovarian, pancreatic and lung cancer cases and controls.Conclusion:This robust, validated study shows autoantibodies to MUC1 peptide or glycopeptides cannot be used for breast, ovarian, lung or pancreatic cancer screening. This has significant implications for research on the use of MUC1 in cancer detection.

U2 - 10.1038/bjc.2013.214

DO - 10.1038/bjc.2013.214

M3 - Journal article

C2 - 23652307

SN - 0007-0920

VL - 108

SP - 2045

EP - 2055

JO - B J C

JF - B J C

IS - 10

ER -

Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this